New cocktail of drugs hopes to tackle Hard-to-Treat colorectal cancer

NCT ID NCT07491159

Ongoing Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of three drugs—fruquintinib, an immunotherapy, and an oral chemo—in people with advanced colorectal cancer that has stopped responding to standard treatments. The goal is to see if this mix can shrink tumors and extend life. About 106 participants will be enrolled at a single center in China.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fruquintinib, immune checkpoint inhibitor, and trifluridine/tipiracil (TAS-102)
What this could lead to: If successful, this combination could offer a new treatment option for patients with advanced colorectal cancer who have run out of standard therapies, potentially improving survival.
What could go wrong: This is an early-phase (Ib/II) trial with only 106 participants, so results may not apply broadly. Combining multiple drugs also raises the risk of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Locations

Tianjin Cancer Hospital

Tianjin, Tianjin Municipality, 300202, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.